Gapping down
In reaction to disappointing earnings/guidance: UBNT -14.9%, AWAY -11.7%, ETH -10.4%, DDD -10.4%, MTSN -9.3%, RMD -8.2%, SPNC -7.9%, MXWL -7.5%, INFY -7.4%, MXIM -7%, DV -6.8%, KN -6.5%, NTGR -4.9%, CVTI -4.5%, XRX -4.5%, VRSN -4.4%, ALTR -3.8%, P -3.7%, SYNA -3.6%, BIIB -3.4%, AZN -3.3%, AMSC -3.2%, (announces a proposed public offering of common stock; size and price considerations not disclosed), MKTO -2.9%, IMGN -2.5%, HBI -2%, IPAR -1.9%, SHOR -1.4%, FSL -1.3%, COF -0.9%, N -0.9%, KLAC -0.6%
Other news: AERI -55% (reports initial Rhopressa Phase 3 efficacy results; trial did not meet its primary efficacy endpoint), STEM -13.4% ( announces proposed public offering of common stock and warrants; Size not disclosed), SPNC -7.9% (announced it is accelerating investments in the Stellarex drug-coated balloon angioplasty platform for treatment of Below the Knee peripheral artery disease), EMES -7.1% (reduces quarterly distribution 29% to $1.00/unit from $1.41/unit), LPCN -5.2% (announces proposed public offering of common stock), AMSC -5% (announced a proposed public offering of common stock; size and price considerations not disclosed), SSYS -4.5% (in sympathy with DDD), PDLI -3% (disclosed that on April 22, 2015, David Montez, Controller and Chief Accounting Officer resigned ), NLSN -2.1% (Announces Secondary Common Stock Offering of 20 mln shares on behalf of selling shareholder)
Analyst comments: BBY -1.8% (downgraded to Neutral from Overweight at JP Morgan), BBT -0.7% (downgraded to Neutral from Buy at Compass Point)
In reaction to disappointing earnings/guidance: UBNT -14.9%, AWAY -11.7%, ETH -10.4%, DDD -10.4%, MTSN -9.3%, RMD -8.2%, SPNC -7.9%, MXWL -7.5%, INFY -7.4%, MXIM -7%, DV -6.8%, KN -6.5%, NTGR -4.9%, CVTI -4.5%, XRX -4.5%, VRSN -4.4%, ALTR -3.8%, P -3.7%, SYNA -3.6%, BIIB -3.4%, AZN -3.3%, AMSC -3.2%, (announces a proposed public offering of common stock; size and price considerations not disclosed), MKTO -2.9%, IMGN -2.5%, HBI -2%, IPAR -1.9%, SHOR -1.4%, FSL -1.3%, COF -0.9%, N -0.9%, KLAC -0.6%
Other news: AERI -55% (reports initial Rhopressa Phase 3 efficacy results; trial did not meet its primary efficacy endpoint), STEM -13.4% ( announces proposed public offering of common stock and warrants; Size not disclosed), SPNC -7.9% (announced it is accelerating investments in the Stellarex drug-coated balloon angioplasty platform for treatment of Below the Knee peripheral artery disease), EMES -7.1% (reduces quarterly distribution 29% to $1.00/unit from $1.41/unit), LPCN -5.2% (announces proposed public offering of common stock), AMSC -5% (announced a proposed public offering of common stock; size and price considerations not disclosed), SSYS -4.5% (in sympathy with DDD), PDLI -3% (disclosed that on April 22, 2015, David Montez, Controller and Chief Accounting Officer resigned ), NLSN -2.1% (Announces Secondary Common Stock Offering of 20 mln shares on behalf of selling shareholder)
Analyst comments: BBY -1.8% (downgraded to Neutral from Overweight at JP Morgan), BBT -0.7% (downgraded to Neutral from Buy at Compass Point)